UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma
Public ClinicalTrials.gov record NCT00580372. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Intensive "TOTAL THERAPY" for Untreated or Minimally Treated Patients With Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This experimental study evaluates the effects of a series of intensive drug regimens as initial treatment for Multiple Myeloma followed by 2 bone marrow transplantations 4-6 months apart in support of high-dose Melphalan, followed by Interferon treatment indefinitely.
Study identification
- NCT ID
- NCT00580372
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 231 participants
Conditions and interventions
Conditions
Interventions
- VAD Drug
- High-Dose cyclophosphamide Drug
- Hemopoietic stem cell procurement Procedure
- EDAP Drug
- Autologous Hemopoietic Stem Cell Transplant 1 Procedure
- Autologous Hemopoietic Stem Cell Transplant 2 Procedure
- Maintenance Drug
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2002
- Primary completion
- Sep 30, 2015
- Completion
- Sep 30, 2015
- Last update posted
- Sep 19, 2016
2002 – 2015
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas for Medical Sciences/MIRT | Little Rock | Arkansas | 72205 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Multiple Myeloma trials
Other public records listing Multiple Myeloma. Sorted by last update posted; newest first. Not a recommendation.
- NCT05201781: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel Recruiting
- NCT07783607: MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma Not yet recruiting
- NCT06152575: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Recruiting
- NCT07776964: Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) Not yet recruiting
- NCT07285239: Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Recruiting
- NCT05976555: Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00580372, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 19, 2016 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00580372 live on ClinicalTrials.gov.